Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sage Therapeutic Com (SAGE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,956,333
  • Shares Outstanding, K 41,050
  • Annual Sales, $ 0 K
  • Annual Income, $ -158,990 K
  • 36-Month Beta 3.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 31.12

Price Performance

See More
Period Period Low Period High Performance
1-Month
153.33 +10.52%
on 12/22/17
180.83 -6.29%
on 01/10/18
+8.09 (+5.01%)
since 12/19/17
3-Month
59.57 +184.47%
on 10/25/17
180.83 -6.29%
on 01/10/18
+106.54 (+169.33%)
since 10/19/17
52-Week
44.55 +280.38%
on 01/30/17
180.83 -6.29%
on 01/10/18
+116.43 (+219.55%)
since 01/19/17

Most Recent Stories

More News
Sage Therapeutics to Provide Pipeline Update at J.P. Morgan Healthcare Conference and Outline Key 2018 Initiatives to Support Planned Evolution to a Fully-Integrated Commercial Biopharmaceutical Company

--- 2018 strategy focuses on continued R&D innovation, pipeline expansion and commercialization plans for new classes of CNS therapeutics -

JPM : 112.75 (-0.23%)
SAGE : 169.46 (+1.65%)
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that,...

SAGE : 169.46 (+1.65%)
Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

JPM : 112.75 (-0.23%)
SAGE : 169.46 (+1.65%)
Pre-Market Technical Scan on Biotech Equities -- Amicus Therapeutics, Radius Health, Sage Therapeutics, and Pulmatrix

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on FOLD, RDUS, SAGE, and PULM which can be accessed for free by signing up to www.wallstequities.com/registration....

FOLD : 15.90 (-1.55%)
PULM : 1.48 (+0.68%)
RDUS : 38.02 (+5.26%)
SAGE : 169.46 (+1.65%)
Sage Therapeutics Soars: Stock Adds 7.1% in Session

Sage Therapeutics (SAGE) was a big mover last session, as the company saw its shares rise more than 7% on the day.

COLL : 23.38 (unch)
SAGE : 169.46 (+1.65%)
Today's Research Reports on Stocks to Watch: Sage Therapeutics and Nektar Therapeutics

NEW YORK, NY / ACCESSWIRE / December 8, 2017 / Sage Therapeutics headed higher on Thursday and hit a brand new high after announcing that its depressive disorder MDD treatment SAGE-217 had seen positive...

SAGE : 169.46 (+1.65%)
NKTR : 71.59 (+2.04%)
Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 169.46 (+1.65%)
Sage Therapeutics, Dollar General jump; LendingClub tumbles

NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday:

EW : 123.91 (+1.80%)
SAGE : 169.46 (+1.65%)
TLRD : 23.49 (+4.96%)
Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder

--- Well-tolerated and demonstrated highly statistically significant mean reduction in the HAM-D score compared to placebo at 15 days (p

SAGE : 169.46 (+1.65%)
Today's Research Reports on Stocks to Watch: Sage Therapeutics and GW Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / November 22, 2017 / Sage Therapeutics shares soared on Tuesday despite any news, but it seems traders were acting favorably to the company announcing the closing of its underwritten...

GWPH : 131.00 (-1.07%)
SAGE : 169.46 (+1.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product...

See More

Key Turning Points

2nd Resistance Point 172.77
1st Resistance Point 171.11
Last Price 169.46
1st Support Level 166.90
2nd Support Level 164.35

See More

52-Week High 180.83
Last Price 169.46
Fibonacci 61.8% 128.77
Fibonacci 50% 112.69
Fibonacci 38.2% 96.61
52-Week Low 44.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.